Executed Document Control Number 99-32-00729 Ex-10.5 LICENSE OPTION AGREEMENTLicense Option Agreement • December 8th, 1999 • Manhattan Scientifics Inc • California
LICENSE OPTION AGREEMENTLicense Option Agreement • December 7th, 2020
THIS LICENSE OPTION AGREEMENT (this “Agreement”), dated as of this ___ day of ____________, 20__ (the “Effective Date”), by and between Hiroshima University, a national university corporation duly organized under the laws of Japan, having a principal address at 1-3-2 Kagamiyama, Higashi-Hiroshima City, Hiroshima Pref., 739-8511, Japan (“University”), and [XYZ Corporation], a corporation duly organized under the laws of ______, having a principal place of business at ___________________, (“XYZ”).
DEINOVE AND GENOPLANTE VALOR AGREEMENT BOOST DEINOCHEM PROGRAMME DEVELOPMENTLicense Option Agreement • December 16th, 2013
Montpellier, December 17th 2013 - DEINOVE (Alternext Paris: ALDEI), a technological company that designs, develops and markets a new generation of industrial processes based on Deinococci bacteria, today announced the signing of a License Option Agreement with Génoplante Valor via INRA Transfert, a research enhancement subsidiary of the French National Institute in Agronomic Research that will cover the improvement of isoprenoid biosynthetic pathways. DEINOVE shall implement this technology in the DEINOCHEM programme to strengthen the Deinococcus bacterium’s capacity to produce chemicals from bio-based raw materials. This intellectual property has been generated as part of an ANR (National Research Agency) Genomics research programme labelled “Génoplante”. Patent details and conditions of acquisition of exploitation rights remain confidential.
LICENSE OPTION AGREEMENTLicense Option Agreement • September 20th, 2023
Parties. The parties to this License Option Agreement (“Agreement”) are Gal Shweiki (“Owner”), and The Landing at Blanco Property Owners Association (the “Association”). Owner owns Lot 38, The Landing at Blanco, Blanco County, Texas, according to plat recorded at Volume 2, Page 44-47, Map and Plat Records of Blanco County (“Lot 38”) and the Association owns Lot 15, The Landing at Blanco, Blanco County, Texas, according to the plat recorded at Volume 2, Page 44-47, Map and Plat Records of Blanco County (“Lot 15”). For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Owner and the Association (the “Parties”) agree as follows:
AMENDMENT NO. 7 TO LICENSE & OPTION AGREEMENTLicense & Option Agreement • March 15th, 2007 • Oscient Pharmaceuticals Corp • Pharmaceutical preparations
THIS AMENDMENT NO. 7 TO THE LICENSE & OPTION AGREEMENT (“Amendment No. 7”) is made and entered into this 27th day of December, 2006 (the “Amendment No. 7 Effective Date”) by and between Oscient Pharmaceuticals Corporation (“OSCIENT”), a Massachusetts corporation, having a principal place of business at 1000 Winter Street, Suite 2200, Waltham, Massachusetts 02451, and LG Life Sciences, LTD (“LGLS”), a corporation organized under the laws of the Republic of Korea, having a principal place of business at LG Twin Tower, 20 yoido-dong, Youngdungpo-gu, Seoul, 150-721, Republic of Korea. LGLS and OSCIENT may be referred to herein individually as a “Party” and collectively as the “Parties”.
24-04-13] Toray, EconCore and Itochu enter into a license option agreement on polyamide honeycomb technologyLicense Option Agreement • June 24th, 2013
After preliminary process and product development work, Toray, EconCore and Itochu decided to enter into an agreement securing an option for a license for the EconCore’s ThermHex technology for Toray.
AMENDMENT NO. 3 TO LICENSE & OPTION AGREEMENTLicense & Option Agreement • December 3rd, 2004 • Oscient Pharmaceuticals Corp • In vitro & in vivo diagnostic substances • California
THIS AMENDMENT NO. 3 TO LICENSE & OPTION AGREEMENT (“the Amendment”) is made and entered into this 16th day of October, 2003 (the “Amendment Effective Date”) by and between GENESOFT PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 7300 Shoreline Court, South San Francisco, CA, USA 94080 (“GS”) and LG LIFE SCIENCES, LTD., a corporation organized under the laws of the Republic of Korea, having its principal place of business at LG Twin Tower, 20 yoido-dong, Youngdungpo-gu, Seoul, 150-721, Republic of Korea (“LGLS”). LGLS and GS may be referred to herein individually as a “Party” and collectively as the “Parties.”
EXHIBIT NO. DESCRIPTION 10.2 License Option Agreement between the Company and Global Dairy Products Ltd. 8/8/97License Option Agreement • February 5th, 1998 • Say Yes Foods Inc • Dairy products
EXHIBIT 10.8 [ALLERGAN LOGO] March 5, 2001 William C. Shepherd Chairman of the Board Allergan Specialty Therapeutics, Inc. 2525 Dupont Irvine, CA 92612 Dear Mr. Shepherd: Pursuant to this letter agreement by and between Allergan, Inc. ("Allergan") and...License Option Agreement • March 9th, 2001 • Allergan Specialty Therapeutics Inc • Pharmaceutical preparations
License Option AgreementLicense Option Agreement • May 16th, 2016 • Immune Pharmaceuticals Inc • Pharmaceutical preparations
This Agreement made this day of May 15, 2016 by and between Immune Pharmaceuticals Inc. (“Immune”) with a principal place of business at 430 East 29th Street, Suite 940, New York, NY 10016 and Novel Pain Therapeutics LLC (“NPT”), a newly formed limited liability company with an office at 52 East End Avenue #12A New York, NY 10028
LICENSE OPTION AGREEMENTLicense Option Agreement • March 14th, 2012 • Biotime Inc • Biological products, (no disgnostic substances) • California
This License Option Agreement (“Agreement”) is made and entered into as of December 15, 2011 (the “Effective Date”), by and between BioTime, Inc., a California corporation (“BioTime”), with offices located at 1301 Harbor Bay Parkway, Suite 100, Alameda, California 94502, and USCN, a Chinese company with offices located at 108 Zhuanyang Avenue Economic & Technological Development Zone, Wuhan 430056 (“USCN”). USCN and BioTime are sometimes hereinafter referred to as the “Parties”.
Toray, EconCore and Itochu enter into a license option agreement on polyamide honeycomb technologyLicense Option Agreement • April 26th, 2013
After preliminary process and product development work, Toray, EconCore and Itochu decided to enter into an agreement securing an option for a license for the EconCore’s
AMENDMENT NO. 1 TO LICENSE OPTION AGREEMENTLicense Option Agreement • July 19th, 2016 • Immune Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Amendment No. 1 to the License Option Agreement (the "Agreement") made and entered into as of the 18th day of July 2016, between Immune Pharmaceuticals Inc., a Delaware corporation (“Immune”) and Novel Pain Therapeutics, LLC., a New York limited liability company (“NPT”), both referred to hereinafter referred to as the "Parties."
MEDIA UPDATELicense Option Agreement • March 7th, 2022
Novartis, Voyager Therapeutics reach license option agreement for next-generation gene therapy vectors for neurological diseases
AMENDMENT NO. 3 TO LICENSE & OPTION AGREEMENTLicense & Option Agreement • May 11th, 2004 • Oscient Pharmaceuticals Corp • In vitro & in vivo diagnostic substances • California
THIS AMENDMENT NO. 3 TO LICENSE & OPTION AGREEMENT (“the Amendment”) is made and entered into this 16th day of October, 2003 (the “Amendment Effective Date”) by and between GENESOFT PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 7300 Shoreline Court, South San Francisco, CA, USA 94080 (“GS”) and LG LIFE SCIENCES, LTD., a corporation organized under the laws of the Republic of Korea, having its principal place of business at LG Twin Tower, 20 yoido-dong, Youngdungpo-gu, Seoul, 150-721, Republic of Korea (“LGLS”). LGLS and GS may be referred to herein individually as a “Party” and collectively as the “Parties.”
THE REGISTRANT HAS APPLIED FOR CONFIDENTIAL TREATMENT OF CERTAIN PROVISIONS OF THIS EXHIBIT WITH THE SECURITIES AND EXCHANGE COMMISSION. THE CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE MARKED WITH ASTERISKS (*****) AND HAVE BEEN OMITTED. THE OMITTED...License & Option Agreement • May 10th, 2005 • Oscient Pharmaceuticals Corp • In vitro & in vivo diagnostic substances
THIS AMENDMENT NO. 4 TO THE LICENSE & OPTION AGREEMENT (“Amendment No. 4”) is made and entered into this 31st day of March, 2005 (the “Amendment No. 4 Effective Date”) by and between Oscient Pharmaceuticals Corporation (formerly Genome Therapeutics Corporation) (“OSCIENT”), a Massachusetts corporation, having a principal place of business at 1000 Winter Street, Suite 2200, Waltham, MA 02451, and LG Life Sciences, LTD (“LGLS”), a corporation organized under the laws of the Republic of Korea, having a principal place of business at LG Twin Tower, 20 yoido-dong, Youngdungpo-gu, Seoul, 150-721, Republic of Korea. LGLS and OSCIENT may be referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDMENT No. 5 TO LICENSE & OPTION AGREEMENTLicense & Option Agreement • May 10th, 2006 • Oscient Pharmaceuticals Corp • Pharmaceutical preparations
THIS AMENDMENT No. 5 TO THE LICENSE & OPTION AGREEMENT (“Amendment No. 5”) is made and entered into this February 3, 2006 (the “Amendment No. 5 Effective Date”) by and between Oscient Pharmaceuticals Corporation (“OSCIENT”), a Massachusetts corporation, having a principal place of business at 1000 Winter Street, Suite 2200, Waltham, MA 02451, and LG Life Sciences, LTD (“LGLS”), a corporation organized under the laws of the Republic of Korea, having a principal place of business at LG Twin Tower, 20 yoido-dong, Youngdungpo-gu, Seoul, 150-721, Republic of Korea. LGLS and OSCIENT may be referred to herein individually as a “Party” and collectively as the “Parties”.
LICENSE OPTION AGREEMENT ------------------------ THIS AGREEMENT, effective the 18th day of December, 1996, is made and entered by and between Palatin Technologies, Inc., a New Jersey corporation, with office 214 Carnegie Center, TES 100, Princeton,...License Option Agreement • September 12th, 1997 • Palatin Technologies Inc • In vitro & in vivo diagnostic substances • New York
